Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo

被引:54
作者
Ermolieff, J
Lin, XL
Tang, J
机构
[1] OKLAHOMA MED RES FDN,PROT STUDIES PROGRAM,OKLAHOMA CITY,OK 73104
[2] UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73104
关键词
D O I
10.1021/bi971072e
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In order to study the basis of resistance of human immunodeficiency virus, type 1 (HIV-I), to HIV-1 protease inhibitor saquinavir, the catalytic and inhibition properties of the wild-type HIV-1 protease and three saquinavir resistant mutants, G48V, L90M, and G38V/L90M, were compared. The kinetic parameter k(cat)/K-M was determined for these proteases using eight peptide substrates whose sequences were derived from the natural processing site sequences of HIV-1. The k(cat)/K-m values were determined using conventional steady-state kinetics as well as initial velocities of mixed substrate cleavages under the condition where the substrate concentrations [S]o << K-m. The independently determined k(cat) and K-m values for some of the substrates confirmed the accuracy of the mixed-substrate method and also permitted the calculation in all cases of true rather than relative k(cat)/K-m values. The K-i values were also determined. Using a previously described kinetic model [Tang, J., & Hartsuck, J. A. (1995) FEES Lett. 367, 112-116], the relative processing activities of HIV-1 protease variants were estimated in the saquinavir concentration range of 0-10(-7) M. Although the protease activity of G48V, L90M, and G48V/L90M are only about 10, 7, and 3% of that of the wild-type HIV-1 protease in the absence of inhibitor, the resistance tendencies of the three mutants are clearly manifest by relatively less activity loss as inhibitor concentration becomes higher. Also, the ratios of the activities of the four protease species at certain saquinavir concentrations appear to correlate with the population ratios of the four protease species at different time points of clinical trials. This correlation suggests that the population ratio of the protease species is driven by in vivo saquinavir concentration, which appears to be in the range 10-(10)-10(-9) M during the clinical trials.
引用
收藏
页码:12364 / 12370
页数:7
相关论文
共 43 条
  • [1] Bieth J., 1974, BAYER S, P463
  • [2] PROTEOLYTIC PROCESSING MECHANISMS OF A MINIPRECURSOR OF THE ASPARTIC PROTEASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    CO, E
    KOELSCH, G
    LIN, YZ
    IDO, E
    HARTSUCK, JA
    TANG, J
    [J]. BIOCHEMISTRY, 1994, 33 (05) : 1248 - 1254
  • [3] HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY
    COFFIN, JM
    [J]. SCIENCE, 1995, 267 (5197) : 483 - 489
  • [4] Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
    Condra, JH
    Holder, DJ
    Schleif, WA
    Blahy, OM
    Danovich, RM
    Gabryelski, LJ
    Graham, DJ
    Laird, D
    Quintero, JC
    Rhodes, A
    Robbins, HL
    Roth, E
    Shivaprakash, M
    Yang, T
    Chodakewitz, JA
    Deutsch, PJ
    Leavitt, RY
    Massari, FE
    Mellors, JW
    Squires, KE
    Steigbigel, RT
    Teppler, H
    Emini, EA
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (12) : 8270 - 8276
  • [5] CONDRA JH, 1995, NATURE, V374, P469
  • [6] ANTIVIRAL PROPERTIES OF RO 31-8959, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PROTEINASE
    CRAIG, JC
    DUNCAN, IB
    HOCKLEY, D
    GRIEF, C
    ROBERTS, NA
    MILLS, JS
    [J]. ANTIVIRAL RESEARCH, 1991, 16 (04) : 295 - 305
  • [7] HIV-1 PROTEASE SPECIFICITY OF PEPTIDE CLEAVAGE IS SUFFICIENT FOR PROCESSING OF GAG AND POL POLYPROTEINS
    DARKE, PL
    NUTT, RF
    BRADY, SF
    GARSKY, VM
    CICCARONE, TM
    LEU, CT
    LUMMA, PK
    FREIDINGER, RM
    VEBER, DF
    SIGAL, IS
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 156 (01) : 297 - 303
  • [8] L-735,524 - THE DESIGN OF A POTENT AND ORALLY BIOAVAILABLE HIV PROTEASE INHIBITOR
    DORSEY, BD
    LEVIN, RB
    MCDANIEL, SL
    VACCA, JP
    GUARE, JP
    DARKE, PL
    ZUGAY, JA
    EMINI, EA
    SCHLEIF, WA
    QUINTERO, JC
    LIN, JH
    CHEN, IW
    HOLLOWAY, MK
    FITZGERALD, PMD
    AXEL, MG
    OSTOVIC, D
    ANDERSON, PS
    HUFF, JR
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (21) : 3443 - 3451
  • [9] ERMOLIEFF J, 1997, IN PRESS ADV EXP MED
  • [10] Fersht A., 1985, ENZYME STRUCTURE MEC